Entact Bio

Entact Bio is a preclinical-stage biotechnology company based in Watertown, Massachusetts, developing a new class of small-molecule precision medicines called Enhancement-Targeting Chimeric (ENTAC) molecules. Where targeted protein degradation removes disease-causing proteins, Entact Bio works in the opposite direction: its ENTAC molecules recruit deubiquitinases (DUBs) to strip ubiquitin chains from beneficial proteins in order to extend their half-life, relocate them, or otherwise restore their function. The company's proprietary Encompass platform combines biological, chemical, and computational tools to identify disease targets amenable to protein enhancement across oncology, autoimmune disease, and rare genetic disorders. Entact Bio launched in December 2022 with an $81 million Series A co-led by Qiming Venture Partners USA and venBio Partners, with participation from Abingworth, Brandon Capital, and others. It is a therapeutics research organization and publishes no public developer program, API, or machine-readable API artifacts.

Entact Bio is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Drug Discovery, and Life Sciences.

Entact Bio’s developer surface includes product news and 9 more developer resources.

🌐 Visit website 📡 Source on GitHub
5.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0
0 APIs
CompanyBiotechnologyPharmaceuticalsDrug DiscoveryLife SciencesTargeted Protein DegradationPreclinical

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0
Composite quality — 5.7/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.0 / 17
Commercial Clarity 0.0 / 17
Operational Transparency 0.0 / 11
Governance 0.0 / 10
Discoverability 4.6 / 9
Regulatory Posture 1.1 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/entactbio: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Entactbio Domain Security

TLSv1.3 · DMARC

SECURITY

Resources

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt
LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Contact
Contact

Company 6

The organization behind the API

Website
Website
 About
About
 News
News
 Careers
Careers
 LinkedIn
LinkedIn
 Crunchbase
Crunchbase

Other 1

Properties that don't map to a standard resource type

Team
Team

Source (apis.yml)

apis.yml Raw ↑ 
aid: entactbio
name: Entact Bio
description: 'Entact Bio is a preclinical-stage biotechnology company based in Watertown, Massachusetts, developing a new
  class of small-molecule precision medicines called Enhancement-Targeting Chimeric (ENTAC) molecules. Where targeted protein
  degradation removes disease-causing proteins, Entact Bio works in the opposite direction: its ENTAC molecules recruit deubiquitinases
  (DUBs) to strip ubiquitin chains from beneficial proteins in order to extend their half-life, relocate them, or otherwise
  restore their function. The company''s proprietary Encompass platform combines biological, chemical, and computational tools
  to identify disease targets amenable to protein enhancement across oncology, autoimmune disease, and rare genetic disorders.
  Entact Bio launched in December 2022 with an $81 million Series A co-led by Qiming Venture Partners USA and venBio Partners,
  with participation from Abingworth, Brandon Capital, and others. It is a therapeutics research organization and publishes
  no public developer program, API, or machine-readable API artifacts.'
url: https://raw.githubusercontent.com/api-evangelist/entactbio/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-12'
modified: '2026-08-12'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Drug Discovery
- Life Sciences
- Targeted Protein Degradation
- Preclinical
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/entactbio-domain-security.yml
- type: Website
  url: https://entactbio.com/
- type: About
  url: https://entactbio.com/science/
- type: Team
  url: https://entactbio.com/team/
- type: News
  url: https://entactbio.com/news-publications/
- type: Careers
  url: https://entactbio.com/careers/
- type: Contact
  url: https://entactbio.com/contact-us/
- type: LinkedIn
  url: https://www.linkedin.com/company/entact-bio
- type: Crunchbase
  url: https://www.crunchbase.com/organization/entact-bio
- type: LLMsTxt
  url: llms/entactbio-llms.txt
x-enrichment:
  date: '2026-08-12'
  status: minimal
  artifacts_added: 4
  pass: local-v1
x-coverage:
  state: blocked
  reason: bot-challenge
  detail: 'entactbio.com is fronted by a SiteGround bot-protection edge that answers every path — including the site root
    and /robots.txt — with HTTP 202, an `sg-captcha: challenge` header and a 180-byte meta-refresh shell pointing at /.well-known/sgcaptcha/,
    so not one page, spec path or /.well-known/ document could be read from the provider''s own host under any user agent;
    DNS separately shows no api./docs./developer./portal. host to retry against, and the company is a preclinical therapeutics
    business with no evident developer program.'
  evidence:
  - url: https://entactbio.com/
    status: 202
  - url: https://entactbio.com/robots.txt
    status: 202
  - url: https://entactbio.com/llms.txt
    status: 202
  - url: https://entactbio.com/openapi.json
    status: 202
  - url: https://entactbio.com/.well-known/agent-card.json
    status: 202
  - url: https://entactbio.com/.well-known/security.txt
    status: 202
  - url: https://api.github.com/orgs/EntactBio
    status: 200
  checked: '2026-08-12'